CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vidac Pharma Holding PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vidac Pharma Holding PLC
20-22 Wenlock Road
LONDON, N1 7GU  United Kingdom Ticker: T9GT9G
Business Summary
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for oncologic and onco-dermatologic diseases. It develops therapeutic candidates designed to modify the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells, with the aim of renormalizing cellular metabolism and selectively inducing programmed cell death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 - Actinic Keratosis (AK), VDA-1102 - Cutaneous T-Cell Lymphoma (CTCL), and VDA-1275-Solid tumors. VDA-1102 - Actinic Keratosis (AK) is a topical small-molecule candidate designed to target abnormal metabolic processes in malignant cutaneous cells. The VDA-1102 - Cutaneous T-Cell Lymphoma (CTCL) is focused on topical ointment in patients with early-stage CTCL (mycosis fungoides).
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Company Secretary NataliiaKronik 1/29/2023 1/29/2023
Director MaxHerzberg 6/28/2021 6/28/2021
Director ChristianPolicard 5/15/2023 5/15/2023
Director YochaiRichter 5/20/2022 5/20/2022
Director JosephTenne 70 5/15/2023 5/15/2023

General Information
Number of Employees: 6 (As of 12/31/2024)
Outstanding Shares: 56,946,204 (As of 6/30/2025)
Stock Exchange: ETR
Fax Number: +44 972779300647


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026